{
    "data": [
        {
            "id": "4381910",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-27T20:17:56-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences Research Update: Dislocation In Valuation Remains",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105793",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "298098",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4381910-edwards-lifesciences-research-update-dislocation-in-valuation-remains"
            }
        },
        {
            "id": "4375132",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-18T10:02:36-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edward Lifesciences: Examining Its Valuation And Fair Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102170",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "292908",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4375132-edward-lifesciences-examining-valuation-and-fair-value"
            }
        },
        {
            "id": "4364757",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-05T14:04:32-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Life Sciences: 15.76% FCF Margin, But With 6.67% Downside Risk And 30% Overvaluation - Time To Prove It",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105793",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "286890",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4364757-edwards-life-sciences-15_76-percent-fcf-margin-6_67-percent-downside-risk-and-30-percent"
            }
        },
        {
            "id": "4364077",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-04T06:24:49-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences Shows Surprising Resilience, And TAVR Remains A Growth Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "286711",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4364077-edwards-lifesciences-shows-surprising-resilience-and-tavr-remains-growth-market"
            }
        },
        {
            "id": "4340419",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-28T03:30:32-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Wait For The Pullback To Buy Edwards Lifesciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "272636",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4340419-wait-for-pullback-to-buy-edwards-lifesciences"
            }
        },
        {
            "id": "4333970",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-24T16:06:48-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: Riding The TAVR Wave",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105616",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "266177",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4333970-edwards-lifesciences-riding-tavr-wave"
            }
        },
        {
            "id": "4333731",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-23T15:10:05-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Here's The Price I'll Start Buying Edwards Lifesciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95006",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "266818",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4333731-price-start-buying-edwards-lifesciences"
            }
        },
        {
            "id": "4319003",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-24T16:46:59-05:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Edwards Lifesciences: A 10-Year, Full-Cycle Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95006",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "257155",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "4081",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4319003-edwards-lifesciences-10-year-full-cycle-analysis"
            }
        }
    ]
}